Literature DB >> 1710402

Plasmacytoid transitional cell carcinoma. Report of a case with initial presentation mimicking multiple myeloma.

A A Sahin1, M Myhre, J Y Ro, N Sneige, R H Dekmezian, A G Ayala.   

Abstract

The case of a 63-year-old man with a previously undescribed morphologic variant of transitional cell carcinoma of the urinary bladder is reported. The patient initially presented with multiple lytic bony metastases of the ribs and skull. Aspiration biopsy of one of the lytic lesions of the skull showed tumor cells with a striking plasmacytoid appearance, similar to the plasma cells seen in myeloma, leading to an initial observer's diagnosis of multiple myeloma. Subsequently, a bladder tumor with the same cytomorphology was found; immunohistochemical and ultra structural studies performed on the aspirated material and on the bladder biopsy specimen clearly established the epithelial nature of this neoplasm.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710402

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  25 in total

1.  Plasmacytoid urothelial carcinoma of the bladder: a case report.

Authors:  Saad Aldousari; Kanishka Sircar; Wassim Kassouf
Journal:  Cases J       Date:  2009-04-28

2.  Perirectal recurrence and intraperitoneal dissemination of urothelial carcinoma as plasmacytoid variant: clinical-imaging-histological findings.

Authors:  Miguel Angel Arrabal-Polo; María Del Carmen Cano-García; Paolo Fabiano; Verónica Martínez-Pagán; Matías Barayobre; Javier González García
Journal:  Int Urol Nephrol       Date:  2015-06-07       Impact factor: 2.370

3.  [Not Available].

Authors:  Mohamed Hicham Benazzouz; Younes Essatara; Hachem Elsayegh; Ali Iken; Lounis Benslimane; Kaoutar Znati; Yassine Nouini
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

4.  Two cases of plasmacytoid variant of urothelial carcinoma of urinary bladder: systemic chemotherapy might be of benefit.

Authors:  Takuji Hayashi; Go Tanigawa; Kazutoshi Fujita; Ryoichi Imamura; Shigeaki Nakazawa; Yoshiyuki Yamamoto; Masahiro Hosomi; Kohki Shimazu; Hiroaki Fushimi; Seiji Yamaguchi
Journal:  Int J Clin Oncol       Date:  2011-07-07       Impact factor: 3.402

5.  The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy.

Authors:  Qiang Li; Melissa Assel; Nicole E Benfante; Eugene J Pietzak; Harry W Herr; Machele Donat; Eugene K Cha; Timothy F Donahue; Bernard H Bochner; Guido Dalbagni
Journal:  Eur Urol Focus       Date:  2017-06-27

6.  Organ-confined plasmacytoid urothelial carcinoma: implication of the lack of expression of the receptor tyrosine kinase MET.

Authors:  Chiemi Saigo; Koji Iinuma; Koji Kameyama; Kosuke Mizutani; Masahiro Nakano; Yusuke Kito; Tamotsu Takeuchi
Journal:  Int J Clin Exp Pathol       Date:  2018-03-01

7.  Plasmacytoid urothelial carcinoma (PUC): Imaging features with histopathological correlation.

Authors:  Andrew D Chung; Nicola Schieda; Trevor A Flood; Ilias Cagiannos; Kien T Mai; Shawn Malone; Christopher Morash; Shaheed W Hakim; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2017-01-12       Impact factor: 1.862

8.  Plasmacytoid urothelial carcinoma of the urinary bladder: a clinical pathological study and literature review.

Authors:  Zhihua Wang; Tong Lu; Lihuan Du; Zhiquan Hu; Qianyuan Zhuang; Youyuan Li; Cong-Yi Wang; Hui Zhu; Zhangqun Ye
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29

9.  Dysregulation of mammalian target of rapamycin pathway in plasmacytoid variant of urothelial carcinoma of the urinary bladder.

Authors:  Nilda D Gonzalez-Roibon; Alcides Chaux; Turki Al-Hussain; Adeboye O Osunkoya; Stephania Martins Bezerra; Jessica Hicks; Jonathan I Epstein; George J Netto
Journal:  Hum Pathol       Date:  2012-10-17       Impact factor: 3.466

Review 10.  Molecular and histopathology directed therapy for advanced bladder cancer.

Authors:  Constantine Alifrangis; Ursula McGovern; Alex Freeman; Thomas Powles; Mark Linch
Journal:  Nat Rev Urol       Date:  2019-07-09       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.